Novartis AG - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US66987V1098
121,00 € 0,00 (0,00%)
2026-06-04
AKTIENPREIS
SecurityDE:NOTA / Novartis AG - Depositary Receipt (Common Stock)
InstitutionCFO4Life Group, LLC
Latest Disclosed Ownership5,010 shares
Latest Disclosed Value $ 765,341
CFO4Life Group, LLC reports 12.24% decrease in ownership of NOTA / Novartis AG - Depositary Receipt (Common Stock)

On May 11, 2026 - CFO4Life Group, LLC filed a 13F-HR form disclosing ownership of 5,010 shares of Novartis AG - Depositary Receipt (Common Stock) (DE:NOTA) valued at $643,785 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 5,709 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of -12.24% during the quarter. The current value of the position is $606,210 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,010 -699 -12.24 765 -2.80 0.1167
2026-02-06 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 5,709 12 0.21 787 7.81 0.1122
2025-11-07 2025-09-30 13F NOVARTIS SPONSORED ADR 66987V109 5,697 146 2.63 731 8.79 0.1062
2025-08-08 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,551 -438 -7.31 672 0.60 0.1050
2025-04-30 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,989 -630 -9.52 668 3.57 0.1124
2025-02-10 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 6,619 379 6.07 644 -10.18 0.1132
2024-11-12 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 6,240 908 17.03 718 26.46 0.1270
2024-07-31 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,332 -1,074 -16.77 568 -8.40 0.1067
2024-05-06 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 6,406 -609 -8.68 620 -12.57 0.1125
2024-02-12 2023-12-31 13F/A-1 NOVARTIS SPONSORED ADR 66987V109 7,015 -136 -1.90 708 -2.75 0.1352
2024-01-24 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 7,015 -136 708 0.1352
2023-10-30 2023-09-30 13F NOVARTIS SPONSORED ADR 66987V109 7,151 886 14.14 728 15.19 0.1682
2023-08-07 2023-06-30 13F NOVARTIS SPONSORED ADR 66987V109 6,265 523 9.11 632 19.70 0.1357
2023-05-03 2023-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,742 -679 -10.57 528 -9.28 0.1200
2023-02-03 2022-12-31 13F NOVARTIS SPONSORED ADR 66987V109 6,421 865 15.57 583 37.91 0.1238
2022-10-19 2022-09-30 13F NOVARTIS SPONSORED ADR 66987V109 5,556 83 1.52 422 -6.84 0.1123
2022-07-20 2022-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,473 -159 -2.82 453 -8.30 0.1124
2022-05-02 2022-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,632 -196 -3.36 494 -3.14 0.1037
2022-02-10 2021-12-31 13F NOVARTIS SPONSORED ADR 66987V109 5,828 -354 -5.73 510 0.79 0.1054
2021-10-12 2021-09-30 13F NOVARTIS SPONSORED ADR 66987V109 6,182 354 6.07 506 -4.89 0.1178
2021-07-14 2021-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,828 -24 -0.41 532 6.40 0.1228
2021-04-20 2021-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,852 192 3.39 500 -6.37 0.1243
2021-01-12 2020-12-31 13F NOVARTIS SPONSORED ADR 66987V109 5,660 0 0.00 534 8.54 0.1531
2020-10-13 2020-09-30 13F NOVARTIS SPONSORED ADR 66987V109 5,660 -224 -3.81 492 -4.28 0.1666
2020-07-15 2020-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,884 67 1.15 514 7.08 0.1975
2020-04-16 2020-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 5,817 -185 -3.08 480 -15.49 0.2567
2020-01-22 2019-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 6,002 -78 -1.28 568 7.58 0.2401
2019-11-01 2019-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 6,080 -2,975 -32.85 528 -36.15 0.2367
2019-07-29 2019-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 9,055 -75 -0.82 827 -5.81 0.3780
2019-04-22 2019-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 9,130 -3,011 -24.80 878 -15.74 0.4113
2019-02-01 2018-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 12,141 -848 -6.53 1,042 -6.88 0.4582
2018-10-25 2018-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 12,989 -2,339 -15.26 1,119 -3.28 0.4962
2018-08-01 2018-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 15,328 15,328 1,157 0.4828
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.